The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cause of death in patients with lower‐risk myelodysplastic syndrome
Open accessAbstract
BACKGROUND: The authors have recently shown that a majority of patients with myelodysplastic syndrome (MDS) classified by the International Prognostic Scoring System as lower risk die without transformation to acute myelogenous leukemia (AML). The cause of death (COD) of these patients is not well understood. Identifying the COD could help to guide early therapy decisions. METHODS: The authors retrospectively analyzed the COD in a cohort of 273 deceased patients with lower‐risk MDS according to the International Prognostic Scoring System at presentation to The University of Texas M. D. Anderson Cancer Center from 1980 to 2004. MDS‐related death was defined as infection, bleeding, transformation to AML, or disease progression. Remaining CODs were classified as non–MDS‐related. RESULTS: Median age at presentation was 66 years (range, 19‐88 years). Overall median survival was 59 weeks (range, 1‐831 weeks). All French‐American‐British leukemia classification subgroups were represented. The percentage of International Prognostic Scoring System low and intermediate‐1 groups were 21% and 79%, respectively. The most common cytogenetic abnormality (9%) was del(5q). Patients received supportive care only. The COD was identified as MDS‐related in 230 of 273 (84%) patients. The most common disease‐related CODs were infection (38%), transformation to AML (15%), and hemorrhage (13%). The most frequent non–disease‐related COD was cardiovascular events (19 of 43 patients). CONCLUSIONS: The majority of patients with low‐ or intermediate‐1 risk MDS will die because of causes related to their underlying disease. Although these results need to be validated in different populations, early therapeutic intervention could be considered in the management of these patients to improve survival. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · cited 1×
“4) Platelet count, 10(3)/L 61 (2-692) WBC, 10(3)/L 3.”
Cited by
Malcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Saunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63
“Survival estimate, median mo (95% CI) 29 (29-30) 12 (11-13) 30 (29-30) 51 (49-53)”
BackgroundAnemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52
Metadata
- Authors
- Dayyani, F., Conley, A. P., Strom, S. S., Stevenson, W., Cortes, J. E., Borthakur, G., Faderl, S., O'Brien, S., Pierce, S., Kantarjian, H., & Garcia‐Manero, G.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-04-20
- Volume
- 116
- Issue
- 9
- Pages
- 2174-2179
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2129580665
- Cited by
- 180
- References
- 2
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.